Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999544 | 0.95 | HSD17B10 (0.41) | ALDH1A1MAPTSMN1; SMN2HPGDCASP3 | |
| SCHEMBL3898404 | 0.95 | HSD17B10 (0.41) | ALDH1A1MAPTSMN1; SMN2HPGDCASP3 | |
| SCHEMBL16826921 | 0.87 | HRH3 (0.40) | ALDH1A1SMN1; SMN2HPGDCASP3EPHX1 | |
| SCHEMBL2261903 | 0.81 | CASP3 (0.43) | SMN1; SMN2HPGDCASP3FKBP1AEPHX1 | |
| SCHEMBL29894062 | 0.81 | HPGD (0.41) | HPGDCASP3FKBP1AEPHX1HSD17B10 | |
| SCHEMBL7538169 | 0.81 | HPGD (0.41) | HPGDCASP3FKBP1AEPHX1HSD17B10 | |
| SCHEMBL17595517 | 0.81 | HPGD (0.41) | HPGDCASP3FKBP1AEPHX1HSD17B10 | |
| SCHEMBL17595518 | 0.81 | HPGD (0.41) | HPGDCASP3FKBP1AEPHX1HSD17B10 | |
| SCHEMBL25730353 | 0.81 | HPGD (0.41) | HPGDCASP3FKBP1AEPHX1HSD17B10 | |
| SCHEMBL18884425 | 0.80 | SMN1; SMN2 (0.49) | ALDH1A1MAPTSMN1; SMN2FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104016977-B | A kind of replacement thiadiazine diketone derivative and preparation method thereof and application | 山东大学 | 2016-06-22 | — | — | CN | claimed |
| WO-2024017381-A1 | COMPOUND FOR INHIBITING IRAK4 ACTIVITY AND USE THEREOF | 深圳众格生物科技有限公司 | 2024-01-25 | — | — | WO | disclosed |
| EP-3833666-B1 | PROCESSES FOR THE PREPARATION OF BOC-LINAGLIPTIN | RICHTER GEDEON NYRT (HU) | 2022-11-02 | — | — | EP | disclosed |
| CN-113607831-B | Detection method of 4-Boc-aminopiperidine related substance | 河北国龙制药有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-113121467-B | Benzothiazole derivative and medical application thereof | 河北师范大学 | 2022-03-29 | — | — | CN | disclosed |
| CN-113607831-A | Detection method of 4-Boc-aminopiperidine related substance | 河北国龙制药有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3833666-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BOC-LINAGLIPTIN | Richter Gedeon Nyrt. (HU) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020031040-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF BOC-LINAGLIPTIN | RICHTER GEDEON NYRT. (HU) | 2020-02-13 | — | — | WO | disclosed |
| CN-107602532-A | A kind of SYR-322 industrialized preparing process | 合肥远志医药科技开发有限公司 | 2018-01-19 | — | — | CN | disclosed |
| EP-3256217-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| WO-2005037207-A2 | ARYLALKYL-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE INCLUDING VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037807-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037809-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004035576-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035577-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| CN-1481376-A | HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS | ���ĵ�˹ҩ��¹�����˾ | 2004-03-10 | — | — | CN | disclosed |
| US-4382892-A | Benzoxazine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1983-05-10 | — | — | US | disclosed |
| EP-0047005-A1 | Benzoxazine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1982-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | ALDH1A1 2541/4885MAPT 4371/4885SMN1; SMN2 3976/4885 |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | ALDH1A1 2541/4885MAPT 4371/4885SMN1; SMN2 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.